Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

71.92
Delayed Data
As of Jun 28
 +1.27 / +1.80%
Today’s Change
63.76
Today|||52-Week Range
88.85
+0.43%
Year-to-Date
Gilead's (GILD) HCV Drug Application Accepted in the EU
Jun 27 / Zacks.com - Paid Partner Content
How to Find the Best Value Stocks
Jun 21 / Zacks.com - Paid Partner Content
AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU
Jun 27 / Zacks.com - Paid Partner Content
Pharma recovers composure as price concerns ease
Jun 21 / FT.com - Paid Partner Content
Biotech stocks bounce as regulation fears ease
Jun 26 / FT.com - Paid Partner Content
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt
Jun 21 / Zacks.com - Paid Partner Content
These Stocks Are Changing Course
Jun 26 / TheStreet.com - Paid Partner Content
Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada
Jun 20 / Zacks.com - Paid Partner Content
Stock Market News for June 23, 2017
Jun 23 / Zacks.com - Paid Partner Content
Is Gilead Sciences a Great Stock for Value Investors?
Jun 16 / Zacks.com - Paid Partner Content
2 Recovering Biotech Names With Room to Run
Jun 23 / TheStreet.com - Paid Partner Content
Epizyme Provides Positive Interim Data on EZH2 Inhibitor
Jun 15 / Zacks.com - Paid Partner Content
Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout
Jun 23 / TheStreet.com - Paid Partner Content
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug
Jun 15 / Zacks.com - Paid Partner Content
The Market Advance Narrows
Jun 22 / TheStreet.com - Paid Partner Content
GSK climbs on setback for competitor's drug
May 30 / FT.com - Paid Partner Content